Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2019 11:30 ET | Source: Precipio, Inc.

Precipio Pathology Sales Metrics Demonstrate Continuous Improvement in Q2 2019

NEW HAVEN, Conn., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the results of three key performance metrics that together...
August 13, 2019 09:15 ET | Source: Precipio, Inc.

Precipio Announces Q2-2019 Corporate Update Call for Shareholders

NEW HAVEN, Conn., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be hosting its Second quarter 2019 corporate update call on Wednesday,...
July 22, 2019 10:00 ET | Source: Precipio, Inc.

Global Expansion Efforts Begin Yielding Results

NEW HAVEN, Conn., July 22, 2019 (GLOBE NEWSWIRE) -- Specialty Diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that in conjunction with its global expansion efforts, it has begun...
June 25, 2019 09:15 ET | Source: Precipio, Inc.

Precipio and H3 Biomedicine Sign Second Development Agreement

NEW HAVEN, Conn., June 25, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced the initiation of a second development project with H3 Biomedicine that...
June 17, 2019 10:39 ET | Source: Precipio, Inc.

Precipio CEO Provides Update Letter To Shareholders

NEW HAVEN, Conn., June 17, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides an update to its shareholders. Dear Investors: We are all aware of the...
June 04, 2019 09:10 ET | Source: Precipio, Inc.

Precipio Signs Exclusive Manufacturing Agreement for IV-Cell™

NEW HAVEN, Conn., June 04, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has entered into an exclusive subcontracting manufacturing...
May 30, 2019 10:15 ET | Source: Precipio, Inc.

Precipio Pathology Sales Performance Metrics Demonstrate Substantial Improvement in Q1-2019

NEW HAVEN, Conn., May 30, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today provides shareholders with three of the key pathology performance metrics...
May 23, 2019 09:55 ET | Source: Precipio, Inc.

Precipio CEO enrolls in long term stock purchase plan

NEW HAVEN, Conn., May 23, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that, as previously stated, Ilan Danieli, Precipio’s CEO, has enrolled...
May 15, 2019 11:40 ET | Source: Precipio, Inc.

Precipio Regains Nasdaq Listing Compliance

NEW HAVEN, Conn., May 15, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on May 15, 2019 the Company received a letter from Nasdaq informing...
May 06, 2019 09:20 ET | Source: Precipio, Inc.

Precipio Conducts IV-Cell™ Validation Trial with a Prominent Laboratory

NEW HAVEN, Conn., May 06, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it is in the process of completing a trial of its Proprietary IV-Cell...